Form 4: Pfizer Director James Quincey Acquires Additional Phantom Stock Units

Pfizer Director James Quincey has acquired 1,598.597 phantom stock units, increasing his beneficial ownership to 69,204.871 units, as part of deferred director's compensation.

Summary

• James Quincey, a Director of Pfizer Inc. (PFE), reported an acquisition of phantom stock units.
• The transaction date for the acquisition was June 30, 2025.
• A total of 1,598.597 Phantom Stock Units were acquired.
• The acquisition price for these units was $24.24 per unit.
• Following this transaction, James Quincey's total beneficial ownership of Phantom Stock Units is 69,204.871.
• Each phantom stock unit represents one phantom share of common stock.
• These units represent deferred director's compensation, including dividend equivalents, and are settled in cash or common stock at the director's election upon retirement from the Board of Directors.

Sentiment

Score: 7

Explanation: The acquisition of additional phantom stock units by a director, even as part of deferred compensation, generally indicates continued alignment of interests with shareholders and confidence in the company's long-term value.

Positives

• Director James Quincey increased his beneficial ownership of Pfizer phantom stock units, which can be interpreted as a signal of continued confidence in the company's future performance and alignment with shareholder interests.

Negatives

• No direct negatives are indicated in this Form 4 filing, which reports an acquisition of phantom stock units as part of deferred compensation.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction related to compensation.

Future Outlook

This Form 4 filing does not provide specific forward-looking statements or guidance regarding Pfizer's future outlook.

Management Comments

• This Form 4 filing does not contain direct quotes or paraphrased statements from company management beyond the transaction details.

Industry Context

Insider transactions, such as the acquisition of phantom stock units by a director, are generally viewed by the market as a potential signal of management's confidence in the company's prospects within the pharmaceutical industry. This specific transaction reflects a component of deferred compensation for a director at a major pharmaceutical company.

Comparison to Industry Standards

• This Form 4 filing, detailing an insider's acquisition of phantom stock units, does not provide information suitable for direct comparison to industry-specific financial benchmarks or competitor results. It primarily reports a compensation-related transaction.

Related Party Transactions

• The acquisition of phantom stock units by Director James Quincey represents a related party transaction as it involves compensation from Pfizer Inc. to a member of its Board of Directors.

Stakeholder Impact

• Shareholders: The acquisition of phantom stock units by a director aligns management's interests with shareholders, as the value of these units is tied to the company's stock performance.

Next Steps

• No specific future actions, events, or milestones are detailed in this Form 4 filing.

Key Dates

Recommendation

Keywords

Pfizer, PFE, Form 4, insider transaction, phantom stock units, director compensation, James Quincey, beneficial ownership